Former President Joe Biden, who disclosed that his prostate cancer has spread to the bones, said recent treatment “sometimes slows me down,” underscoring the reality faced by men with high‑grade metastatic disease.
What Gleason 9 Means
Pathologists assign a Gleason score by adding two grades that reflect how much cancer cells differ from normal prostate tissue. Scores range from 6 to 10; a score of 9, as in Biden’s case, falls in Grade Group 5, the most aggressive category. This level of differentiation signals rapid growth and a high likelihood of spread.
Prognosis for Metastatic Prostate Cancer
When prostate cancer has reached distant sites such as bone, five‑year survival rates fall to roughly 30‑40 %. By contrast, men whose disease remains confined to the prostate enjoy 10‑year survival above 99 %.
Standard Treatment Pathway
Initial therapy for advanced disease typically begins with androgen deprivation therapy (ADT), which lowers circulating testosterone that fuels tumor growth. If cancer cells continue to progress despite ADT, the condition is termed castration‑resistant prostate cancer and is treated with continued hormone therapy plus the chemotherapy drug docetaxel.
For high‑risk localized or locally advanced cases, radiotherapy combined with ADT is standard. The phase‑3 ENZARAD trial examined whether adding the androgen‑receptor inhibitor enzalutamide to ADT and radiotherapy improved outcomes. Overall, enzalutamide did not significantly extend metastasis‑free or overall survival, though a subgroup receiving pelvic lymph‑node radiation showed a lower risk of metastasis or death.
Managing Bone Health and Quality of Life
Bone metastases cause pain, risk of fractures, and reduced mobility. Hormone therapy can alleviate symptoms, but patients often experience hot flashes, fatigue, and loss of bone density. Integrative approaches such as meditation and yoga have been reported to support emotional well‑being during treatment. Regular PSA testing remains the primary tool for monitoring disease activity and treatment response.
Emerging Precision Radiotherapy
Advances in adaptive radiation therapy (ART) and stereotactic body radiation therapy (SBRT) allow clinicians to target tumors with high precision while sparing surrounding tissue, reducing treatment courses to as few as five sessions. Patients like Cecil Foster have reported minimal fatigue and rapid return to daily activities after such regimens.
What This Means for Patients
Early findings suggest that hormone‑sensitive metastatic prostate cancer can be managed with a combination of ADT, targeted chemotherapy, and, where appropriate, advanced radiotherapy. Quality of life can be preserved through supportive care and vigilant monitoring. However, the aggressive nature of Gleason 9 disease means survival expectations are modest, and treatment plans must be individualized.
Patients should discuss the full range of options—including clinical trial participation, bone‑protective agents, and integrative therapies—with their oncology team.
For those navigating insurance coverage or budgeting for long‑term care, understanding the sequence of ADT, possible chemotherapy, and periodic imaging can help anticipate out‑of‑pocket costs and plan financially.
Talk to your doctor or oncologist about the best strategy for your situation.
Sources
- Biden’s cancer Is slowing him down ahead of his memoir’s release
- Prostate cancer
- Integrative medicine helps prostate cancer survivor heal
- Prostate cancer recurrence: Cecil’s story
- Enzalutamide Fails to Improve Survival in High-Risk Prostate Cancer | Targeted Onc – Immunotherapy, Biomarkers, and Cancer Pathways
- Joe Biden reveals he will not be able to have 'as many conversations' in heartbreaking prostate cancer update
Photo: National Cancer Institute / Unsplash (Unsplash License)
